AstraZeneca, GlaxoSmithKline, Johnson & Johnson and the 3 world-leading universities (Imperial College London, University College London and the University of Cambridge) have joined forces to found the ‘Apollo’ Bridge.
This pioneering new joint venture, the Apollo Therapeutics Fund, will support the translation of ground-breaking academic science from within these universities into innovative new medicines for a broad range of diseases.
Each of the three industry partner companies (AstraZeneca, Glaxo Group and J&J Innovation) will contribute £10M (€13.15M) over 6 years to the venture.
The technology transfer offices (TTOs) of the three university partners – Imperial Innovations, Cambridge Enterprise and UCL Business – will each contribute a further £3.3M (€4.34M).
Apollo will be advised by an independent Drug Discovery Team (DDT) of ex-industry scientists,